Sierra Leone
West African state; Ebola 2014 frontline country, now an ARILAC AMR surveillance programme participant.
Sierra Leone joined ARILAC, a four-year programme launched on 6 May 2026 to build antimicrobial-resistance testing in eight African states. Across 14 countries assessed, only 1.3% of medical laboratories ran routine resistance tests.
Last refreshed: 4 October 2026 · Appears in 1 active topic
Does Sierra Leone's Ebola frontline experience translate into meaningful AMR laboratory capacity for ARILAC?
Timeline for Sierra Leone
Mentioned in: WHO: 2,000 Congolese workers get Ervebo
Pandemics and BiosecurityMentioned in: Uganda and DRC shut their shared border
Pandemics and BiosecurityMentioned in: Ebola reaches two more DRC provinces
Pandemics and BiosecurityMentioned in: Most Ebola deaths never reach a ward
Pandemics and BiosecurityMentioned in: A second Ebola centre walks out on pay
Pandemics and BiosecurityBackground
Sierra Leone is a West African coastal state of about 8 million people (2024 estimate), bordered by Guinea and Liberia. Freetown is its capital and main port, and its economy rests on agriculture and artisanal diamond mining. A civil war against the Revolutionary United Front rebels ran from 1991 to 2002 and wrecked much of its infrastructure.
The 2014-16 West African Ebola epidemic, caused by the Zaire species, hit Sierra Leone harder than any other country, with more than 14,000 cases and about 3,900 deaths. The country also hosted STRIVE, a 2015 vaccine trial among health workers that could not measure efficacy because cases fell too fast, and ended as a safety study. Vaccine trials in DR Congo's 2026 Bundibugyo outbreak face the same risk.
Foreign donors paid for much of the health system Sierra Leone rebuilt after 2016. ARILAC, the continental antimicrobial-resistance laboratory programme it joined in May 2026, builds on that base.
Sierra Leone joins a resistance-testing network
Sierra Leone was named on 6 May 2026 as one of eight African Union member states in ARILAC, a four-year programme that Africa CDC, the African Society for Laboratory Medicine and the EU launched in Addis Ababa. Of more than 50,000 medical laboratories assessed in 14 African countries, only 1.3% ran routine resistance tests, leaving 261 million people without local resistance data.
For Sierra Leone the programme builds on laboratories rebuilt after the 2014-16 Ebola epidemic. On 23 May 2026 the World Health Assembly adopted a ten-year Global Action Plan on Antimicrobial Resistance, aiming to cut bacterial resistance deaths by 10% by 2030. That plan binds no government, so ARILAC's laboratory work is where Sierra Leone's part in it takes practical shape.
Late hazard pay sparked strikes here before
During the 2014-16 Ebola epidemic, Sierra Leone's government and its partners set up dedicated combat-pay and hazard-allowance funds to keep front-line responders at their posts. Delays in paying those allowances repeatedly set off strikes among the people treating patients.
That record became a reference point in July 2026, when health workers in DR Congo's Ituri Province walked off the job over unpaid hazard pay and delayed salaries. On 25 July staff at a second treatment centre, Elikya, walked out. Sierra Leone's experience points to the same weak link: money pledged by donors keeps a ward staffed only when wages reach the workers on time.
How did the 2014 Ebola outbreak change Sierra Leone's health system?
What is ARILAC and why is Sierra Leone part of it?
Why did Sierra Leone set up hazard-pay funds during the 2014 Ebola outbreak?
How does the 2026 Ituri health worker strike compare to Sierra Leone's Ebola pay disputes?
